Pencarian obat berdasarkan namanya

Zumandimine dan Intoleransi glukosa

Hasil pengujian interaksi obat Zumandimine dan penyakit Intoleransi glukosa untuk kontraindikasi dan efek samping dengan penggunaan bersama.

Hasil pengecekan:

Zumandimine <> Intoleransi glukosa

Aktualitas: 23.07.2019 Pemeriksa: Dr. P.M.Shkutko, in

Sesuai dengan informasi sumber yang dapat diandalkan Drugs.com, Rxlist.com, Webmd.com, Medscape.com, saat pemeriksaan interaksi efek samping dan kontraindikasi ditemukan, yang dapat membahayakan atau meningkatkan efek negatif saat penggunaan kombinasi obat-obatan dengan penyakit yang terkait.

Konsumen:

Gangguan toleransi glukosa telah diamati pada beberapa pasien diberikan kontrasepsi oral dan tampaknya terkait terutama dengan dosis estrogen. Namun, progestogen dapat meningkatkan sekresi insulin dan menghasilkan resistensi insulin untuk berbagai derajat, tergantung pada agen. Pasien dengan diabetes mellitus harus dipantau lebih dekat selama terapi dengan estrogen dan/atau progestogen, dan penyesuaian dibuat sesuai dalam regimen antidiabetik.

Sumber

"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho Pharmaceutical Corporation, Raritan, NJ.
Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6
Stubblefield PG "Choosing the best oral contraceptive." Clin Obstet Gynecol 32 (1989): 316-28
Belchetz PE "Hormonal treatment of postmenopausal women." N Engl J Med 330 (1994): 1062-71
Luciano AA, De Souza MJ, Roy MP, Schoenfeld MJ, Nulsen JC, Halvorson CV "Evaluation of low-dose estrogen and progestin therapy in postmenopausal women." J Reprod Med 38 (1993): 207-14
Steinberg WM "Oral contraception: risks and benefits." Adv Contracept 5 (1989): 219-28
Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4
Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6
Derman R "Oral contraceptives: a reassessment." Obstet Gynecol Surv 44 (1989): 662-8
"Product Information. Ortho Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho Pharmaceutical Corporation, Raritan, NJ.
"Product Information. Ortho Novum 1/50 (mestranol-norethindrone)." Ortho Pharmaceutical Corporation, Raritan, NJ.
"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
"Product Information. Micronor (norethindrone)" Ortho McNeil Pharmaceutical, Raritan, NJ.
"Product Information. Demulen (ethinyl estradiol-ethynodiol)." Searle, Skokie, IL.
Kaunitz AM "Long-acting injectable contraception with depot medroxyprogesterone acetate." Am J Obstet Gynecol 170 (1994): 1543-9
"Product Information. Ovrette (norgestrel)" Wyeth-Ayerst Laboratories, Philadelphia, PA.
Garg SK, Chase HP, Marshall G, Hoops SL, Holmes DL, Jackson WE "Oral contraceptives and renal and retinal complications in young women with insulin-dependent diabetes mellitus." JAMA 271 (1994): 1099-102
"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32
"Product Information. Norplant System (levonorgestrel)" Wyeth-Ayerst Laboratories, Philadelphia, PA.
"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho Pharmaceutical Corporation, Raritan, NJ.
"Product Information. Ortho-Novum (oral contraceptive combination pill)." Ortho Pharmaceutical Corporation, Raritan, NJ.
Who Task Force on Long-acting Agents for Fertility Regulation "Metabolic side-effects of injectable depot-medroxyprogesterone acetate, 150 mg three-monthly, in undernourished lactating women." Bull World Health Organ 64 (1986): 587-94